Core Viewpoint - Kelun Pharmaceutical (002422) announced on September 1 that approximately 35% of its R&D expenses are allocated to generic drugs, while around 60% is dedicated to innovative drugs, with the remainder for raw materials and other areas [1] R&D Expense Allocation - Generic drugs account for about 35% of the R&D investment [1] - Innovative drugs represent approximately 60% of the R&D investment [1] - The remaining portion is allocated to raw materials and other segments [1] Future Trends - The R&D investment in innovative drugs is expected to continue growing in line with clinical progress and product development [1] - The R&D investment in generic drugs is anticipated to remain relatively stable based on the trends observed over the past two years [1]